Clinical trials: Influenza Human
Virus Diseases, RNA Virus Infections
Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.
A phase I trial conducted in a single centre, observer-blind, randomized, dose-ranging, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of 2 intramuscular injections of plant-based H7 VLP…
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT02022163
- Testing
- Low dose of H7 VLP vaccine + Alhydrogel, Med dose of H7 VLP vaccine + Alhydrogel, High dose of H7 VLP vaccine + Alhydrogel
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Medicago
Influenza
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)
This trial will assess the immunogenicity and safety elicited by the adjuvanted GSK Biologicals' influenza investigational vaccine GSK2340274A in healthy Japanese adults aged 20-64 years.
- Trial name
- NCT00989612
- Testing
- Influenza investigational vaccine GSK2340274A
- Where
- 2 sites in Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring
Primary Objective: To evaluate the safety of Flublok Quadrivalent influenza vaccine in pregnant women included in the VAP00003 Study (NCT03694392) and their offspring exposed during pregnancy or up to 28 days preceding the…
- Trial name
- VAP00007 (NCT04460781)
- Testing
- Flublok Quadrivalent influenza vaccine RIV4, Standard-dose quadrivalent inactivated influenza vaccine SD-IIV4
- Where
- United States
- Volunteers
- 96,175 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza Prevention
Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine
To evaluate the protective effect 14 days after the live attenuated influenza vaccine; To evaluate the protective effect of vaccination with live attenuated influenza vaccine; To evaluate the safety of freeze-dried nasal spray…
- Trial name
- NCT06280144
- Testing
- Influenza Vaccine, Live, Nasal, Freeze-dried, Sterile water for inhalation
- Where
- China
- Volunteers
- 6,080 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Influenza, Human
Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects
The purpose of this study is to describe the immunogenicity and safety of the cell culture-derived influenza vaccine compared with the egg-derived influenza vaccine among subjects.
- Trial name
- NCT02344134
- Testing
- NBP607, Agrippal S1
- Volunteers
- 1,155 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Influenza
A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in Adults
This study is designed to test the immunogenicity and reactogenicity of the Fluarix™/Influsplit SSW® influenza vaccine containing the influenza strains recommended for the 2008-2009 season.
- Trial name
- NCT00706563
- Testing
- Fluarix™
- Where
- 5 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.
The purpose of this study is to determine the efficacy of the liquid formulation of CAIV-T against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months.
- Trial name
- NCT00192400
- Testing
- CAIV-T
- Volunteers
- 2,160 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Study Measuring the Safety, Immunogenicity and Lot Consistency of Cell Derived Influenza Vaccine
A phase 3 study to obtain additional safety and immunogenicity data on Solvay's cell-derived seasonal trivalent subunit influenza vaccine in adult and elderly subjects without significant illnesses and to demonstrate consistency…
- Trial name
- NCT00999206
- Testing
- Influenza Vaccine
- Where
- 19 sites in Australia, New Zealand
- Volunteers
- 3,138 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
Seasonal Influenza, Hand, Foot and Mouth Disease
The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine
The purpose of this study is to evaluate the Immunogenicity and safety of the simultaneously vaccination of Inactivated Enterovirus 71 Vaccine (EV71) and seasonal influenza vaccine(SIV)
- Trial name
- NCT04133584
- Testing
- EV71 +SIV, EV71, SIV
- Where
- China
- Volunteers
- 1,134 people
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Influenza
Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)
This was a Phase 1/2, randomized, observer-blinded, active-controlled trial to assess the Safety and Tolerability of a Recombinant Trivalent Nanoparticle Influenza Vaccine (Tri-NIV) with Matrix M1™ Adjuvant in Healthy Older…
- Trial name
- NCT03293498
- Testing
- NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21
- Where
- 3 sites in United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza
Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children
A study to assess whether the Northern Hemisphere 2009/2010 season influenza vaccine Inflexal V is as immunogenic as a locally sourced competitor vaccine in young children.
- Trial name
- NCT01310400
- Testing
- Inflexal V, Agrippal
- Where
- China
- Volunteers
- 1,356 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza
Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)
The investigators collected blood and lymphoid tissues routinely discarded during surgery from adults after a routine seasonal influenza vaccination to determine how immune memory develops at the actual site of infection, and how…
- Trial name
- NCT03023709
- Testing
- Fluzone®, FluMist®
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Stanford University
Antioxidative Stress, Cold
Taxifolin/Ergothioneine and Immune Biomarkers in Healthy Volunteers (TaxEr)
The complexities of the immune system make measuring the impact of dietary interventions upon its function challenging. The immune system is highly responsive to environmental influences, including the diet.
- Conditions
- Antioxidative Stress, Cold, Influenza, Aging
- Trial name
- TaxEr (NCT05190432)
- Testing
- Taxifolin, Ergothioneine, Control
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Southampton
Influenza, Human
Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents
This study is a multi-center, randomized, double-blind Phase III clinical trial. The aim of the study is to describe the immunogenicity and safety of the quadrivalent cell culture-derived influenza vaccine compared to the…
- Trial name
- NCT02621164
- Testing
- NBP607-QIV, Agrippal S1
- Volunteers
- 454 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Avian Influenza, Influenza
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults
This is a Phase I randomized, double-blind, controlled trial in 275 males and non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT02624219
- Testing
- AS03, MF59 adjuvant, Monovalent Influenza A/H5N8 vaccine
- Where
- 4 sites in United States
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults
The purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA)…
- Trial name
- NCT06431607
- Testing
- F2G22B/DL001Z, F2H23D/DL001Z-NH, F2H23B/DL001Z-NH
- Where
- 18 sites in United States
- Volunteers
- 845 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Panblok H7 Vaccine Adjuvanted With AS03 or MF59
The main purpose of this study is to assess the safety and ability of a Panblok H7 influenza vaccine adjuvanted with AS03 or MF59 to generate an immune response after 2 doses separated by 28 days.
- Trial name
- NCT03283319
- Testing
- 3.75 ug Panblok H7, 7.5 ug Panblok H7, 15 ug Panblok H7
- Where
- 4 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
Human Influenza
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above
The present study is designed to confirm the safety and immunogenicity of trivalent, surface antigen, inactivated influenza vaccine in 2 age cohorts: 18 to ≤60 years and ≥61 years.
- Trial name
- NCT01879553
- Testing
- TIV
- Where
- Belgium
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
COVID -19, Influenza A
Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings
The Metrix Respiratory Panel Test will be evaluated for use in Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein.
- Conditions
- COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus
- Trial name
- NCT07217639
- Testing
- Aptitude Medical Systems Respiratory Panel Test
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Aptitude Medical Systems
Influenza
A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age
The purpose of the study was to find out if children 5 through 8 years of age who are getting influenza vaccine for the first time should get one or two doses.
- Trial name
- NCT00158665
- Testing
- 2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
- Where
- United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente